14/02/2024  16:40:47 Chg. - Volume Bid09:25:00 Demandez à09:24:28 Capitalisation boursière Dividende Y. Rapport P/E
390.90EUR - 4
Chiffrre d'affaires: 1,563.60
399.55Bid taille: 100 402.70Ask la taille: 100 103.73 Mrd.EUR - -

Description de l'entreprise

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
 

Conseil d'administration & Conseil de surveillance

PDG
Reshma Kewalramani, M.D.
Conseil d'administration
Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D.
Conseil de surveillance
Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay
 

Données de l'entreprise

Nom: Vertex Pharmaceuticals Inc.
Adresse: 50 Northern Avenue,Boston, Massachusetts 02210, USA
Téléphone: +1-617-961-7163
Fax: -
Courriel: Investorinfo@VRTX.com
Internet: www.vrtx.com/
Industrie: Healthcare
Secteur: Pharmaceutical Industry
Sous-secteur: Pharmaceuticals
Fin de l'exercice financier: 31/12
Flotte libre: 82.70%
IPO date: 24/07/1991

Relations avec les investisseurs

Nom: Susie Lisa
Téléphone IR: +1-617-341-6108
IR-Fax: -
E-mail IR: investorinfo@vrtx.com

Principaux actionnaires

Autres
 
52.58%
Blackrock Inc.
 
8.84%
Vanguard Group Inc
 
8.48%
Capital World Investors
 
6.72%
FMR, LLC
 
5.67%
State Street Corporation
 
4.78%
Wellington Management Group, LLP
 
2.93%
Alliancebernstein L.P.
 
2.92%
Price (T.Rowe) Associates Inc
 
2.62%
Autres
 
4.46%